Cited by 609Hepatocellular Carcinoma Treatment and PrognosisLiver Disease Diagnosis and TreatmentHead and Neck Cancer Studies

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team

Open access

Dyson, Jessica, Jaques, Bryan, Chattopadyhay, Dipankar, Lochan, Rajiv, Graham, Janine, Das, Debasish, Aslam, Tahira, Patanwala, Imran, Gaggar, Sameer, Cole, Michael, Sumpter, Kate, Stewart, Stephen, Rose, John, Hudson, Mark, Manas, Derek, Reeves, Helen L.·2014·Journal of Hepatology

DOI 10.1016/j.jhep.2013.08.011

Open this paper in CoChat — free account

Abstract

Background & aims Hepatocellular cancer (HCC) commonly complicates chronic liver disease and increases in incidence have been reported despite falling prevalences of viral hepatitis.Methods Following the introduction of centralised specialist teams to manage patients with cancer in England, we characterised the demographics of patients with HCC referred to the Newcastle-upon-Tyne Hospitals NHS Foundation Trust between 2000 and 2010. Regional HCC mortality data was from Public Health England.Results HCC related mortality in the region rose 1.8 fold in 10 years, from 2.0 to 3.7 per 100,000. 632 cases were reviewed centrally, with 2-3 fold increases in referrals of patients with associated hepatitis C, alcoholic liver disease or no chronic liver disease and a >10 fold increase in HCC associated with non-alcoholic fatty liver disease (NAFLD). By 2010 NAFLD accounted for 41/118 (34.8%) cases. Irrespective of associated etiologies, metabolic risk factors were present in 78/118 (66.1%) cases in 2010, associated with regional increases in obesity and diabetes. Median overall survival was just 10.7 months. Although patients with NAFLD associated HCC were older (71.3 yr vs. 67.1 yr; p<0.001) and their cancers less often detected by surveillance, their survival was similar to other etiologies. This was attributed to significantly higher incidental presentation (38.2%) and lower prevalence of cirrhosis (77.2%).Conclusions HCC related mortality is increasing, with typical patients being elderly with metabolic risk factors. The prognosis for most of the cases is poor, but older patients with co-morbidities can do well, managed, within a specialist multidisciplinary team if their cancer is detected pre-symptomatically.

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2013.08.011

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,913
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Estimates of the cancer incidence and mortality in Europe in 2006
Ferlay, J., Autier, P., Boniol, M., Heanue, M., Colombet, M., & Boyle, P. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl498 · Cited by 4,032
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Estimates of cancer incidence and mortality in Europe in 2008
Ferlay, J., Parkin, D. M., & Steliarova‐Foucher, E. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2009.12.014 · Cited by 2,323
Nonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
Neuschwander‐Tetri, B. A., & Caldwell, S. H. (2003) · Hepatology · doi:10.1053/jhep.2003.50193 · Cited by 2,166
The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis
Ascha, M. S., Hanouneh, I. A., Lopez, R., Tamimi, T. A.-R., Feldstein, A. F., & Zein, N. N. (2010) · Hepatology · doi:10.1002/hep.23527 · Cited by 1,296

Show all 25 references

Sorted by citations

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Hepatocellular carcinoma
Forner, A., Reig, M., & Bruix, J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30010-2 · Cited by 5,774
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Burden of liver diseases in the world
Asrani, S. K., Devarbhavi, H., Eaton, J., & Kamath, P. S. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.09.014 · Cited by 3,783
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
Johnson, P. J., Berhane, S., Kagebayashi, C., Satomura, S., Teng, M. J., Reeves, H. L., O’Beirne, J. P., Fox, R., Skowrońska, A., Palmer, D. H., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.9151 · Cited by 2,865
Global burden of liver disease: 2023 update
Devarbhavi, H., Asrani, S. K., Arab, J. P., Nartey, Y. A., Pose, E., & Kamath, P. S. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.017 · Cited by 2,267
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
“, chronic HBV or HCV), where cirrhosis is already present in ~90% of people (Dyson et al., 2014; Mittal et al., 2016; Paradis et al., 2009; Piscaglia et al., 2016).”
Background
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030
Estes, C., Anstee, Q. M., Arias, M., Bantel, H., Bellentani, S., Caballería, J., Colombo, M., Craxì, A., Crespo, J., Day, C. P., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.05.036 · Cited by 2,046
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
Huang, D. Q., El-Serag, H. B., & Loomba, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00381-6 · Cited by 1,855
From NASH to HCC: current concepts and future challenges
Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O., & Heikenwalder, M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0145-7 · Cited by 1,392
Self-citation
Epidemiology and surveillance for hepatocellular carcinoma: New trends
Singal, A. G., Lampertico, P., & Nahon, P. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.025 · Cited by 1,149
Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management
McPherson, S., Hardy, T., Henderson, E., Burt, A. D., Day, C. P., & Anstee, Q. M. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.11.034 · Cited by 1,059
“Those patients who progress to cirrhosis are at risk of potentially life threatening liver-related complications such as portal hypertension, hepatic failure and hepatocellular carcinoma [9–13].”
Background
NAFLD and diabetes mellitus
Tilg, H., Moschen, A. R., & Roden, M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.147 · Cited by 1,002
Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy
Singal, A. G., Kanwal, F., & Llovet, J. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00825-3 · Cited by 1,029
“In the UK, a review of 632 consecutive patients with HCC referred to Newcastle-upon-Tyne Hospitals NHS Foundation Trust revealed that the proportion with MASLD-related HCC increased tenfold to >34.8% within one decade (2000–2010) 56 .”
BackgroundInfluential
Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates
Younossi, Z., Stepanova, M., Ong, J., Jacobson, I., Bugianesi, E., Duseja, A., Eguchi, Y., Wong, V., Negro, F., Yılmaz, Y., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.05.057 · Cited by 702
Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis
Marengo, A., Rosso, C., & Bugianesi, E. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-090514-013832 · Cited by 757
Changing epidemiology, global trends and implications for outcomes of NAFLD
Wong, V. W.-S., Ekstedt, M., Wong, G. L.-H., & Hagström, H. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.036 · Cited by 765
Non-alcoholic fatty liver disease: An expanded review
Benedict, M., & Zhang, X. (2017) · World Journal of Hepatology · doi:10.4254/wjh.v9.i16.715 · Cited by 788
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), & European Association for the Study of Obesity (EASO) (2016) · Diabetologia · doi:10.1007/s00125-016-3902-y · Cited by 695
TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease
Liu, Y.-L., Reeves, H. L., Burt, A. D., Tiniakos, D., McPherson, S., Leathart, J. B. S., Allison, M. E. D., Alexander, G. J., Piguet, A.-C., Anty, R., et al. (2014) · Nature Communications · doi:10.1038/ncomms5309 · Cited by 623
Self-citation
The Natural Course of Non-Alcoholic Fatty Liver Disease
Bertot, L. C., & Adams, L. A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050774 · Cited by 638
Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum
Hardy, T., Oakley, F., Anstee, Q. M., & Day, C. P. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044224 · Cited by 641
“8% of HCCs in NAFLD were in noncirrhotic patients (86).”
Background
Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis
Williams, R. L., Aspinall, R., Bellis, M. A., Camps-Walsh, G., Cramp, M., Dhawan, A. K., Ferguson, J., Forton, D. M., Foster, G. R., Gilmore, S. I., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61838-9 · Cited by 601
Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States
Younossi, Z. M., Stepanova, M., Ong, J. P., Trimble, G., Alqahtani, S. A., Younossi, I. M., Ahmed, A., Racila, A., & Henry, L. L. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.05.064 · Cited by 603
Recent insights into the pathogenesis of nonalcoholic fatty liver disease
Arab, J. P., Arrese, M., & Trauner, M. (2018) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043617 · Cited by 573
Liver Ultrasound Elastography: An Update to the World Federation for Ultrasound in Medicine and Biology Guidelines and Recommendations
Ferraioli, G., Wong, V. W., Castéra, L., Berzigotti, A., Sporea, I., Dietrich, C. F., Choi, B. I., Wilson, S. R., Kudo, M., & Barr, R. G. (2018) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2018.07.008 · Cited by 574
“Non-alcoholic fatty liver disease (NAFLD) is becoming the most common cause of chronic liver disease and a risk factor for HCC (Dyson et al. 2014).”
BackgroundInfluential
Risk Factors, Patterns, and Outcomes of Late Recurrence After Liver Resection for Hepatocellular Carcinoma: A Multicenter Study From China
Xu, X.-F., Xing, H., Han, J., Li, Z.-L., Lau, W.-Y., Zhou, Y.-H., Gu, W.-M., Wang, H., Chen, T.-H., Zeng, Y.-Y., et al. (2019) · JAMA Surgery · doi:10.1001/jamasurg.2018.4334 · Cited by 532
Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma
Liu, Y.-L., Patman, G. L., Leathart, J. B. S., Piguet, A.-C., Burt, A. D., Dufour, J.-F., Day, C. P., Daly, A. K., Reeves, H. L., & Anstee, Q. M. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.02.030 · Cited by 549
“However, if the results of the current study are corroborated, PNPLA3 rs738409 genotype could potentially be included in a broader multi-factorial risk assessment to help physicians to identify those amongst the expanding population of obese individuals with NAFLD at greatest risk of HCC, both in the presence and abse…”
Result
Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer
Huang, D. Q., Singal, A. G., Kono, Y., Tan, D. J. H., El‐Serag, H. B., & Loomba, R. S. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.05.003 · Cited by 557
EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease
European Association for the Study of the Liver (EASL), E. A. F. T. S. O. D. (. (2016) · Obesity Facts · doi:10.1159/000443344 · Cited by 531
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
(2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 545
Obesity is an independent risk factor for non‐alcoholic fatty liver disease: evidence from a meta‐analysis of 21 cohort studies
Li, L., Liu, D., Yan, H., Wang, Z., Zhao, S. ‐., & Wang, B. (2016) · Obesity Reviews · doi:10.1111/obr.12407 · Cited by 462
NAFLD and liver transplantation: Current burden and expected challenges
Pais, R., Barritt, A. S., Calmus, Y., Scatton, O., Runge, T. M., Lebray, P., Poynard, T., Ratziu, V., & Conti, F. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.07.033 · Cited by 445
Obesity and cancer: inflammation bridges the two
Kolb, R. H., Sutterwala, F. S., & Zhang, W. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.07.005 · Cited by 431
Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus
Targher, G., Lonardo, A., & Byrne, C. D. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.173 · Cited by 397
Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores
Bianco, C., Jamialahmadi, O., Pelusi, S., Baselli, G., Dongiovanni, P., Zanoni, I., Santoro, L., Maier, S., Liguori, A., Meroni, M., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.024 · Cited by 385
“Upon confirmation by further studies, this relationship would suggest that approaches/drugs ai ming to reduce liver fat may contribute to prevent HCC.(4-7,31) As we exploited simple yet very robust PRS based o n a limited number of validated risk variants that can be used irrespective of the prese nce of liver disease…”
The evolving epidemiology of hepatocellular carcinoma: a global perspective
Wallace, M. C., Preen, D. B., Jeffrey, G. P., & Adams, L. A. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.1028363 · Cited by 374
“Across that period, there was a greater than 10-fold increase in cases associated with NAFLD; and by 2010, NAFLD accounted for more than one-third of all new cases [14].”
Background
Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment
Llovet, J. M., Willoughby, C. E., Singal, A. G., Greten, T. F., Heikenwälder, M., El-Serag, H. B., Finn, R. S., & Friedman, S. L. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00754-7 · Cited by 354
Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver
Dongiovanni, P., Stender, S., Pietrelli, A., Mancina, R. M., Cespiati, A., Petta, S., Pelusi, S., Pingitore, P., Badiali, S., Maggioni, M., et al. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12719 · Cited by 367
Epidemiology and risk-stratification of NAFLD-associated HCC
Ioannou, G. N. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.08.012 · Cited by 361
Steatotic liver disease
Israelsen, M. E., Francque, S., Tsochatzis, E. A., & Krag, A. A. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01811-7 · Cited by 381
Update in global trends and aetiology of hepatocellular carcinoma
Rawla, P., Sunkara, T., Muralidharan, P., & Raj, J. P. (2018) · Współczesna Onkologia · doi:10.5114/wo.2018.78941 · Cited by 332
“In industrialised countries, fatty liver disease, apart from viral hepatitis, is closely related to nutritional factors [67].”
Background
Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients
Berhane, S., Toyoda, H., Tada, T., Kumada, T., Kagebayashi, C., Satomura, S., Schweitzer, N., Vogel, A., Manns, M. P., Benckert, J., et al. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.12.042 · Cited by 324
“We assessed the performance of BALAD-2 in patients with different stages of HCC. RESULTS: In all cohorts, the area under the receiver operating characteristic curve (AUROC), quantifying the ability of GALAD to discriminate patients with HCC from patients with chronic liver disease, was greater than 0.90—similar to the…”
BackgroundInfluential
Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts
Alexander, M., Loomis, A. K., van der Lei, J., Duarte-Salles, T., Prieto-Alhambra, D., Ansell, D., Pasqua, A., Lapi, F., Rijnbeek, P., Mosseveld, M., et al. (2019) · BMC Medicine · doi:10.1186/s12916-019-1321-x · Cited by 317
Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European Liver Transplant Registry study
Haldar, D., Kern, B., Hodson, J., Armstrong, M. J., Adam, R., Berlakovich, G., Fritz, J., Feurstein, B., Popp, W., Karam, V., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.04.011 · Cited by 313
Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis
Tan, D. J. H., Ng, C. H., Lin, S. Y., Pan, X. H., Tay, P., Lim, W. H., Teng, M., Syn, N., Lim, G., Yong, J. N., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00078-x · Cited by 307
GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis
Best, J., Bechmann, L. P., Sowa, J., Sydor, S., Dechêne, A., Pflanz, K., Bedreli, S., Schotten, C., Geier, A., Berg, T., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.11.012 · Cited by 296
Current epidemiology in hepatocellular carcinoma
Konyn, P., Ahmed, A., & Kim, D. (2021) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1991792 · Cited by 283
“This has led to an increase in NAFLD-related HCC across Western Europe[75], with single-center studies from the United Kingdom (UK)[76], Germany[77], and Italy [78] showing up to a threefold increase in the proportion of”
Background
Association of Weight Loss Interventions With Changes in Biomarkers of Nonalcoholic Fatty Liver Disease
Koutoukidis, D. A., Astbury, N. M., Tudor, K., Morris, E. M., Henry, J. A., Noreik, M., Jebb, S. A., & Aveyard, P. N. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.2248 · Cited by 279
MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals
Donati, B., Dongiovanni, P., Romeo, S., Meroni, M., McCain, M., Miele, L., Petta, S., Maier, S., Rosso, C., Luca, L. D., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-04991-0 · Cited by 257
Non‐alcoholic fatty liver disease: a review of epidemiology, risk factors, diagnosis and management
Huang, T. (., Behary, J., & Zekry, A. (2020) · Internal Medicine Journal · doi:10.1111/imj.14709 · Cited by 227
NAFLD‐related hepatocellular carcinoma: The growing challenge
Shah, P. A., Patil, R., & Harrison, S. A. (2022) · Hepatology · doi:10.1002/hep.32542 · Cited by 270
“observed more than a 10‐fold increase in NAFLD‐ related HCC between 2000 and 2010, and the elderly population with DM or metabolic syndrome (MetS) had the highest HCC‐associated mortality.[12] F IGURE 1 Temporal trends of NAFLD‐related hepatocellular carcinoma (HCC) in different countries.”
Background
Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management
Marjot, T., Moolla, A., Cobbold, J. F., Hodson, L., & Tomlinson, J. W. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz009 · Cited by 228
Epidemiological and etiological variations in hepatocellular carcinoma
Sagnelli, E., Macera, M., Russo, A., Coppola, N., & Sagnelli, C. (2019) · Infection · doi:10.1007/s15010-019-01345-y · Cited by 228
CXCR2 inhibition enables NASH-HCC immunotherapy
Leslie, J., Mackey, J. B. G., Jamieson, T. J., Ramon‐Gil, E., Drake, T. M., Fercoq, F., Clark, W. A., Gilroy, K. L., Hedley, A., Nixon, C., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-326259 · Cited by 230
Neutrophils as potential therapeutic targets in hepatocellular carcinoma
Geh, D., Leslie, J., Rumney, R., Reeves, H. L., Bird, T. G., & Mann, D. A. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00568-5 · Cited by 223
Incidence of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression
Orci, L. A., Sanduzzi-Zamparelli, M., Caballol, B., Sapena, V., Colucci, N., Torres, F., Bruix, J., Reig, M., & Toso, C. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.05.002 · Cited by 218
Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values
Petta, S., Wong, V. W., Cammà, C., Hiriart, J., Wong, G. L., Marra, F., Vergniol, J., Chan, A. W. H., Marco, V. D., Merrouche, W., et al. (2016) · Hepatology · doi:10.1002/hep.28843 · Cited by 213
“This picture makes NAFLD as the most common cause of chronic liver disease((1)) as a dramatically growing risk factor for hepatocellular carcinoma,((2)) as a leading indication for liver transplantation,((3)) and as a condition leaving individuals at increased risk of extrahepatic—mostly cardiovascular—morbidity and m…”
BackgroundMethod
Immunotherapy for hepatocellular carcinoma: Current and future
Johnston, M. P., & Khakoo, S. I. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i24.2977 · Cited by 196
Monitoring occurrence of liver-related events and survival by transient elastography in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease
Petta, S., Sebastiani, G., Viganò, M., Ampuero, J., Wai-Sun Wong, V., Boursier, J., Berzigotti, A., Bugianesi, E., Fracanzani, A. L., Cammà, C., et al. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.06.045 · Cited by 197
Management of non-alcoholic fatty liver disease
Petroni, M. L., Brodosi, L., Bugianesi, E., & Marchesini, G. (2021) · BMJ · doi:10.1136/bmj.m4747 · Cited by 193
Influence of Metabolic Risk Factors on Risk of Hepatocellular Carcinoma and Liver-Related Death in Men With Chronic Hepatitis B: A Large Cohort Study
Yu, M., Lin, C., Liu, C., Yang, S.-H., Tseng, Y.-L., & Wu, C. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.07.001 · Cited by 176
Should we undertake surveillance for HCC in patients with NAFLD?
Younes, R., & Bugianesi, E. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.10.006 · Cited by 165
Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment
Granito, A., Muratori, L., Lalanne, C., Quarneti, C., Ferri, S., Guidi, M., Lenzi, M., & Muratori, P. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i22.2994 · Cited by 175
Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002–2033: the ITA.LI.CA database
Vitale, A., Svegliati‐Baroni, G., Ortolani, A., Cucco, M., Riva, G. V. D., Giannini, E. G., Piscaglia, F., Rapaccini, G., Marco, M. D., Caturelli, E., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-324915 · Cited by 177
Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?
Valenti, L., Bugianesi, E., Pajvani, U., & Targher, G. (2016) · Liver International · doi:10.1111/liv.13185 · Cited by 171
“(47) have further assessed the risk of incident T2DM at 5 years of follow-up in the following three subgroups of subjects: (1) in those in whom there was resolution of NAFLD over 5 years; (2) in those in whom there was a development of new NAFLD between baseline and the follow-up examinations; and (3) in subjects in w…”
Background
Non-alcoholic fatty liver disease: A sign of systemic disease
Reccia, I., Jayant, K., Akladios, C. Y., Virdis, F., Pai, M., Habib, N., & Spalding, D. R. C. (2017) · Metabolism · doi:10.1016/j.metabol.2017.04.011 · Cited by 171
Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations
Kumar, R., Priyadarshi, R., & Anand, U. (2019) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2019.00051 · Cited by 176
“A recent large population - based Surveillance, Epidemiology and End Results (known as the SEER) study has demonstrated a 9% annual increase in NAFLD-related HCC between 2004 and 2009.45 Dyson et al.46 noted a nearly 10 - fold increase in NAFLD - related HCC cases in the UK from 2000 to 2010.”
BackgroundInfluential
The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma
Wang, H., Rao, B., Lou, J., Li, J., Liu, Z., Li, A., Cui, G., Ren, Z., & Yu, Z. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00055 · Cited by 170
Clinical impact of sexual dimorphism in non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH)
Burra, P., Bizzaro, D., Gonta, A., Shalaby, S., Gambato, M., Morelli, M. C., Trapani, S., Floreani, A., Marra, F., Brunetto, M. R., et al. (2021) · Liver International · doi:10.1111/liv.14943 · Cited by 165
The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2
Day, C. P., & Anstee, Q. M. (2015) · Seminars in Liver Disease · doi:10.1055/s-0035-1562947 · Cited by 169
“71,72 The rise in the burden of NAFLD coincides with a marked increase in the incidence of HCC in many countries, 73 – 76 and so it is timely to also consider whether genetic modi ﬁ ers such as PNPLA3 may also increase the risk of NAFLD-associated HCC. 82 – 84 This association is supported by a…”
Global Epidemiology of Hepatocellular Carcinoma
Singh, S. P., Madke, T., & Chand, P. (2024) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2024.102446 · Cited by 178
Serial combination of non‐invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD
Petta, S., Wong, V. W., Cammà, C., Hiriart, J., Wong, G. L., Vergniol, J., Chan, A. W. H., Marco, V. D., Merrouche, W., Chan, H. L., et al. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14219 · Cited by 159
Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD
Takahashi, H., Kessoku, T., Kawanaka, M., Nonaka, M., Hyogo, H., Fujii, H., Nakajima, T., Imajo, K., Tanaka, K., Kubotsu, Y., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1696 · Cited by 153
Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease.
Degasperi, E., & Colombo, M. (2016) · The Lancet Gastroenterology and Hepatology · doi:10.1016/s2468-1253(16)30018-8 · Cited by 144
Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease
Grimaudo, S., Pipitone, R. M., Pennisi, G., Celsa, C., Cammà, C., Marco, V. D., Barcellona, M. R., Boemi, R., Enea, M., Giannetti, A., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.08.011 · Cited by 152
Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors
Dongiovanni, P. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i36.12945 · Cited by 145
Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD
Reeves, H. L., Zaki, M. Y. W., & Day, C. P. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4085-6 · Cited by 153
Mechanisms Linking Excess Adiposity and Carcinogenesis Promotion
Pérez-Hernández, A. I., Catalán, V., Gómez‐Ambrosi, J., RodrÃguez, A., & FrÃ¼hbeck, G. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00065 · Cited by 148
Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis
Petta, S., Sebastiani, G., Bugianesi, E., Viganò, M., Wong, V. W.-S., Berzigotti, A., Fracanzani, A. L., Anstee, Q. M., Marra, F., Barbara, M., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.05.019 · Cited by 140
“chronic liver disease and cirrhosis [1], an increasing risk factor for hepatocellular carcinoma [2], and the emerging indication for liver transplantation [3].”
Non-alcoholic fatty liver disease and risk of type 2 diabetes
Lallukka, S., & Yki‐Järvinen, H. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.06.006 · Cited by 146
Progression and Natural History of Nonalcoholic Fatty Liver Disease in Adults
Marengo, A., Jouness, R. I. K., & Bugianesi, E. (2015) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.10.010 · Cited by 136
Temporal trends, clinical patterns and outcomes of NAFLD‐related HCC in patients undergoing liver resection over a 20‐year period
Pais, R., Fartoux, L., Goumard, C., Scatton, O., Wendum, D., Rosmorduc, O., & Ratziu, V. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14261 · Cited by 129
“NAFLD accounted for 35% of HCC cases in 2010 and metabolic risk factors were present in 66% of all HCC cases.(4) In the USA, an analysis of MarketScan Research Database between 2002 and 2008, revealed that NAFLD (alone or associated with other causes of chronic liver disease) was the leading risk factor for HCC in 59%…”
Background
Imagestream detection and characterisation of circulating tumour cells – A liquid biopsy for hepatocellular carcinoma?
Ogle, L. F., Orr, J. G., Willoughby, C. E., Hutton, C., McPherson, S., Plummer, R., Boddy, A. V., Curtin, N. J., Jamieson, D., & Reeves, H. L. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.014 · Cited by 130
Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study
Gawrieh, S., Dakhoul, L., Miller, E., Scanga, A., deLemos, A., Kettler, C., Burney, H., Liu, H., Abu-Sbeih, H., Chalasani, N., et al. (2019) · Alimentary Pharmacology and Therapeutics · doi:10.1111/apt.15464 · Cited by 118
Nonalcoholic fatty liver disease burden: Australia, 2019–2030
Adams, L. A., Roberts, S. K., Strasser, S. I., Mahady, S. E., Powell, E. E., Estes, C., Razavi, H. A., & George, J. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15009 · Cited by 130
Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma
Gerbes, A. L., Zoulim, F., Tilg, H., Dufour, J., Bruix, J., Paradis, V., Salem, R., Peck‐Radosavljevic, M., Galle, P. R., Greten, T. F., et al. (2017) · Gut · doi:10.1136/gutjnl-2017-315068 · Cited by 127
Experience with regorafenib in the treatment of hepatocellular carcinoma
Granito, A., Forgione, A., Marinelli, S., Renzulli, M., Ielasi, L., Sansone, V., Benevento, F., Piscaglia, F., & Tovoli, F. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848211016959 · Cited by 126
MASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges
Phoolchund, A. G. S., & Khakoo, S. I. (2024) · Cancers · doi:10.3390/cancers16020259 · Cited by 137
“In cases of non-cirrhotic HCC, as individuals are generally not in a surveillance programme, lesions are more likely to be picked up incidentally or symptomatically (the latter in particular making curative treatment very unlikely) [58].”
Background
Rare pathogenic variants predispose to hepatocellular carcinoma in nonalcoholic fatty liver disease
Pelusi, S., Baselli, G., Pietrelli, A., Dongiovanni, P., Donati, B., McCain, M. V., Meroni, M., Fracanzani, A. L., Romagnoli, R., Petta, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-39998-2 · Cited by 125
Self-citation
Geographical similarity and differences in the burden and genetic predisposition of NAFLD
Yip, T. C., Gómez, E. V., Petta, S., Yilmaz, Y. N., Wong, G. L., Adams, L. A., de Lédinghen, V., Sookoian, S. C., & Wong, V. W. (2022) · Hepatology · doi:10.1002/hep.32774 · Cited by 127
“8% of them with cirrhosis).[72] Notably, although NAFLD overall accounted for 21.”
Background
The changing scenario of hepatocellular carcinoma in Italy: an update
Garuti, F., Neri, A., Avanzato, F., Gramenzi, A., Rampoldi, D., Rucci, P., Farinati, F., Giannini, E., Piscaglia, F., Rapaccini, G., et al. (2014) · Liver international (Print) · doi:10.1111/liv.14735 · Cited by 94
Metabolic dysfunction-associated steatotic liver disease and the heart
Driessen, S., Francque, S., Anker, S. D., Cabezas, M. C., Grobbee, D. E., Tushuizen, M. E., & Holleboom, A. G. (2023) · Hepatology · doi:10.1097/hep.0000000000000735 · Cited by 133
“…MASH, in turn, relates to liver-related mortality and all-cause mortality, and it may lead to cirrhosis and HCC. [1,9] The burgeoning problem of MASLD is a major health issue for the forthcoming decades, driving the incidence of HCC [10] and becoming a major indication for liver transplantation.”
Bariatric Surgery Reduces Cancer Risk in Adults With Nonalcoholic Fatty Liver Disease and Severe Obesity
Rustgi, V. K., Li, Y., Gupta, K., Minacapelli, C. D., Bhurwal, A., Catalano, C., & Elsaid, M. I. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.03.021 · Cited by 125
Human biomimetic liver microphysiology systems in drug development and precision medicine
Gough, A., Soto-Gutierrez, A., Vernetti, L., Ebrahimkhani, M. R., Stern, A. M., & Taylor, D. L. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00386-1 · Cited by 117
NAFLD and MAFLD as emerging causes of HCC: A populational study
Myers, S., Neyroud‐Caspar, I., Spahr, L., Gkouvatsos, K., Fournier, E., Giostra, E., Magini, G. M., Frossard, J., Bascaron, M.-E., Vernaz, N., et al. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100231 · Cited by 119
“8-fold increase in HCC mortality between 2000 and 2010 and a high prevalence of metabolic risk factors but this study was also limited by potential referral bias.(20) A Japanese multicentric study also found that the proportion of patients with non-viral HCC increased from 10% in 1991 to 24% in 2010.”
Background
Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment
Dash, S., Aydın, Y., Widmer, K., & Nayak, L. (2020) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s221187 · Cited by 131

Authors: Dyson, J., Jaques, B., Chattopadyhay, D., Lochan, R., Graham, J., Das, D., Aslam, T., Patanwala, I., Gaggar, S., Cole, M., Sumpter, K., Stewart, S., Rose, J., Hudson, M., Manas, D., & Reeves, H. L.
Affiliations: Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
Newcastle University (GB)
Corresponding author: Reeves, Helen L.
ORCID: Dyson, Jessica
Das, Debasish
Patanwala, Imran
Cole, Michael
Stewart, Stephen
Hudson, Mark
Manas, Derek
Reeves, Helen L.
Venue: Journal of Hepatology
Publisher: Elsevier BV
Published: 2014-01
Volume: 60
Issue: 1
Pages: 110-117
ISSN: 0168-8278 (ISSN-L)
DOI: 10.1016/j.jhep.2013.08.011
OpenAlex: W2076341209
Cited by: 603
References: 25
Citations by year: 2026: 23 · 2025: 32 · 2024: 45 · 2023: 43 · 2022: 72 · 2021: 65 · 2020: 63 · 2019: 60 · 2018: 57 · 2017: 48 · 2016: 38 · 2015: 33 · 2014: 18
FWCI: 19.26
Type: journal article
Language: en
Open access: green
zenodo.org
Licence: other-oa
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Journal of Hepatology (publishedVersion)
PubMed (publishedVersion)
Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, other-oa)
Newcastle University ePrints (Newcastle Univesity)
Topics: Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
Keywords: hepatocellular carcinoma, obesity, type 2 diabetes, non-alcoholic fatty liver disease, HCC mortality, chronic liver disease, hepatitis C, alcoholic liver disease, metabolic risk factors, multidisciplinary cancer care, cancer surveillance, liver cirrhosis, overall survival, cancer incidence trends
MeSH terms: Age Factors, Aged, Diabetes Mellitus, Type 2, Fatty Liver, Humans, Liver Neoplasms, Middle Aged, Obesity, Risk Factors, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks